Johnson & Johnson (JNJ)

Johnson & Johnson - Johnson & Johnsons RYBREVANTFASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer